Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Catalyst Pharmaceutical completes type B meeting with FDA for Firdapse

Jan. 8, 2014

Cytomedix completes enrollment in RECOVER-Stroke trial of ALD-401 in cerebral ischemic stroke

Jan. 8, 2014

Receptos initiates phase III portion of RADIANCE trial of RPC-1063 for relapsing MS

Jan. 8, 2014

Neurocrine reports data from Kinect 2 study of NBI-98854 in tardive dyskinesia

Jan. 7, 2014

Japanese group discloses new OX1/OX2 receptor antagonists

Jan. 7, 2014

Taisho Pharmaceutical prepares new GlyT1 inhibitors for neurological and other disorders

Jan. 7, 2014

TauRx adds new U.S. centers to clinical trials of investigational treatment for Alzheimer's disease

Jan. 7, 2014

First-in-class hKCC2 enhancers for the treatment of neurological diseases

Jan. 7, 2014

Enrollment open in phase IIa study of THR-18 in stroke patients treated with tPA

Jan. 3, 2014

Eisai launches Fycompa for partial-onset seizures in patients with epilepsy

Jan. 3, 2014

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026